Literature DB >> 26866663

Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.

Antonia Bainschab1, Franz Quehenberger2, Hildegard T Greinix1, Robert Krause3, Albert Wölfler1, Heinz Sill1, Armin Zebisch4.   

Abstract

Survival of acute myeloid leukemia (AML) patients, who are unfit for high-dose chemotherapy, has significantly improved with the advent of low-intensity therapeutic regimens (LITR, comprising decitabine, azacitidine, and low-dose cytarabine). However, infectious complications are common during LITR treatment and might hamper the beneficial effect of these drugs. In this study, we aimed to evaluate the incidence of and predisposing risk factors for infections during LITR treatment of AML, as well as the value of antibiotic prophylaxis within this setting. Therefore, we retrospectively analyzed 40 AML patients, treated with 215 cycles of LITR and analyzed putative risk factors by multivariate logistic regression. Infections occurred in 53/215 (25%) of LITR cycles, resulting in death in six patients. Of the parameters assessed at the start of each LITR cycle, transfusion dependence (p=0.008) and increased LDH (p=0.027) independently predicted the occurrence of infection. Most importantly, however, antibiotic prophylaxis was independently associated with a decreased rate of infectious complications (p=0.030). It was regularly performed in neutropenic patients and even managed to eliminate low neutrophil counts as risk factor in multivariate models. These data argue for the efficacy of antibiotic prophylaxis during LITR therapy of AML and suggest its further evaluation within a prospective clinical trial.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; Antibiotic prophylaxis; Infection; Low-intensity treatment regimen

Mesh:

Substances:

Year:  2016        PMID: 26866663     DOI: 10.1016/j.leukres.2016.01.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  5 in total

Review 1.  Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs.

Authors:  Armin Zebisch; Stefan Hatzl; Martin Pichler; Albert Wölfler; Heinz Sill
Journal:  Int J Mol Sci       Date:  2016-12-10       Impact factor: 5.923

2.  Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy.

Authors:  Seung-Hwan Shin; Byung-Sik Cho; Sung-Soo Park; Sung-Yeon Cho; Young-Woo Jeon; Jae-Ho Yoon; Seung-Ah Yahng; Sung-Eun Lee; Dong-Gun Lee; Ki-Seong Eom; Yoo-Jin Kim; Seok Lee; Chang-Ki Min; Seok-Goo Cho; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Hee-Je Kim
Journal:  Oncotarget       Date:  2017-12-23

Review 3.  Noncoding RNAs in cancer therapy resistance and targeted drug development.

Authors:  Wen-Tao Wang; Cai Han; Yu-Meng Sun; Tian-Qi Chen; Yue-Qin Chen
Journal:  J Hematol Oncol       Date:  2019-06-07       Impact factor: 17.388

4.  Long-Term Follow-Up of Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine: A Real-World Study of the Apulian Hematological Network.

Authors:  Michelina Dargenio; Giuseppe Tarantini; Nicola Cascavilla; Enzo Pavone; Pellegrino Musto; Patrizio Mazza; Lorella Melillo; Domenico Pastore; Attilio Guarini; Caterina Buquicchio; Maria Paola Fina; Vincenzo Federico; Teresa Maria Santeramo; Marina Aurora Urbano; Mariangela Leo; Vera Carluccio; Paola Carluccio; Mario Delia; Daniela Carlino; Carolina Vergine; Vito Pier Gagliardi; Giuseppina Greco; Silvia Sibilla; Mariachiara Abbenante; Giovanni Rossi; Giuseppina Spinosa; Annamaria Mazzone; Lara Aprile; Vincenza de Fazio; Crescenza Pasciolla; Giorgina Specchia; Nicola Di Renzo
Journal:  Cancers (Basel)       Date:  2022-02-06       Impact factor: 6.639

Review 5.  Management of the Older Patient with Myelodysplastic Syndrome.

Authors:  Rory M Shallis; Amer M Zeidan
Journal:  Drugs Aging       Date:  2021-08-03       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.